KemPharm (NASDAQ:KMPH) reported Q2 EPS of ($0.70), $0.56 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.75 million.
KemPharm (NASDAQ:KMPH) reported Q2 EPS of ($0.70), $0.56 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.75 million.